Similar Posts
If You Can Only Exercise On Weekends, That’s Still Great For Your Health, A Study Suggests
The “weekend warrior” exercise pattern once dismissed by experts as not quite good enough may not be so bad after all. A study in this week’s JAMA Network Open finds that people who walk 8,000 or more steps a day once or twice a week achieve cardiovascular benefits and lower mortality rates that are almost…
Integrating Fitness into a Busy Schedule: Exercise Routines for the Active Professional
In today’s fast-paced world, balancing work, personal life, and fitness can be a daunting challenge. Busy professionals often find it difficult to carve out time for exercise amidst their hectic schedules. However, integrating fitness into a busy routine is not only possible but also essential for maintaining overall health and productivity. Here are practical tips…
Annual breast cancer screenings linked to lower risk of death, study finds
Making breast cancer screenings an annual event could save women’s lives, new research suggests. In a study led by Epic Research, a health analytics firm based in Verona, Wisconsin, women who were screened for breast cancer on a yearly basis were shown to have a 17% lower risk of death by any cause compared to…
States have been eliminating taxes on period products for years. Here’s where you’ll still pay them.
Packages of Tampax brand tampons on a drugstore shelf in New York on Wednesday, February 10, 2016. Richard Levine | Corbis News | Getty Images Over a lifetime, period products in the U.S. cost a total of around $6,000 per person, according to research published in 2021 — and that’s before tax. In 21 states, a sales tax…
If you can’t build the next Ozempic, buy it: Where M&A could be heading in the obesity drug space
Investors are contemplating where and when the next big obesity drug deal will occur. At the moment, Novo Nordisk and Eli Lilly have the growing obesity drug market all to themselves. But given the potential size of this opportunity, which some have put at more than $100 billion by 2030 , other pharmaceuticals companies —…
Catalent’s Indiana plant to make Novo’s Wegovy weight-loss drug | Reuters News Agency
Health 25 August 2023, 6:39 pm 1 minute Reuters exclusively reported that Novo Nordisk has hired Thermo Fisher as its second contract manufacturer for its hugely popular weight-loss drug Wegovy. Novo Chief Financial Officer Karsten Munk Knudsen told Reuters in May the company had signed up a second contract manufacturer in the United States, but…
